1
Recommendations from HCV-HIV International Panel advise current treatment with pegylated interferon plus ribavirin.
2
Up to now, experience with pegylated interferon and ribavirin is scarce in this population.
3
Use of pegylated interferon was more frequent in Poland and Romania than in other countries.
4
Limited data exist on depression during pegylated IFN-alpha therapy.
5
The fluorescence of BSA was strongly quenched by the binding of pegylated Pur to BSA.
6
The current standard in hepatitis C treatment consists of combination regimens of pegylated interferon-alpha plus ribavirin.
7
We compared the incidence of hypersensitivity reaction associated with IV versus IM administration of pegylated ASNase.
8
Background: Many patients with chronic hepatitis C have not responded to therapy with pegylated interferon plus ribavirin.
9
Biologic therapy was continued and the infection was successfully treated with pegylated interferon, which achieved a sustained virologic response.
10
Besides its disordered structure, the pegylated protein showed a lower unfolding rate at the active-site than the unmodified ones.
11
Conclusions: Transaminase elevations during treatment of chronic Hepatitis C virus with pegylated interferon and ribavirin are common but rarely severe.
12
Hence pegylated interferon plus ribavirin in full doses is effective pre and post transplant but has a low SVR rate.
13
Hepatic steatosis is associated with increased hepatic fibrosis and a reduced level of sustained virological response to pegylated interferon and ribavirin.
14
Treatment of chronic hepatitis C with pegylated interferon-a and ribavirin is now adapted individually based on the virological response on treatment.
15
There has been a recent interest in using ASP in adults with ALL, particularly the less toxic pegylated (PEG) formulation.
16
Interferon alfa, pegylated interferon alfa and five direct antiviral nucleoside and nucleotide analogues are approved for the treatment of chronic hepatitis B.
